Clinical Trial Update: Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

View source ↗

Summary

An update on expanded-access use of REGENECYTE (umbilical cord blood) infusions for patients with Post-COVID-19 Condition-related chronic fatigue.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue Syndrome
• Long Covid
• Post-covid-19 Condition

Drugs mentioned

• REGENECYTE (umbilical cord blood infusion)

Snippet

Sponsor: StemCyte, Inc. | Conditions: Post-COVID-19 Condition, Post-COVID Condition | Status: AVAILABLE